An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis

Barbara Ulmasov, Hidenao Noritake, Peter Carmichael, Kiyoko Oshima, David W. Griggs, Brent A. Neuschwander‐Tetri – 27 December 2018 – The presence and stage of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) is strongly associated with mortality. Thus, both preventing and reversing fibrosis are critically important approaches to prevent death or the need for liver transplantation from NASH.

Feasibility and Safety of Split‐Liver Transplantation in a Nascent Framework of Deceased Donation

Ramkiran Cherukuru, Mettu Srinivas Reddy, Naresh P. Shanmugam, Rajesh Rajalingam, Venugopal Kota, Vasanthakumar Gunasekaran, Gomathy Narasimhan, Ilankumaran Kaliamoorthy, Mohamed Rela – 26 December 2018 – Split‐liver transplantation (SLT) is a valuable option for optimizing the use of good‐quality deceased donor grafts. It is not routinely reported outside the West because of limited deceased donor numbers, technical and organizational constraints, lack of experience, and a predominant living donor liver transplantation (LDLT) practice.

Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.

Pevonedistat, a Neuronal Precursor Cell‐Expressed Developmentally Down‐Regulated Protein 8–Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus

Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Takahiro Seimiya, Tatsunori Suzuki, Eri Tanaka, Rei Ishibashi, Kazuyoshi Funato, Kazuhiko Koike – 26 December 2018 – Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV‐related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented.

Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Fasiha Kanwal, Elliot B. Tapper, Chanda Ho, Sumeet K. Asrani, Nadia Ovchinsky, John Poterucha, Avegail Flores, Victor Ankoma‐Sey, Bruce Luxon, Michael Volk – 26 December 2018 – Health care delivery is increasingly evaluated according to quality measures, yet such measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the American Association for the Study of Liver Diseases was charged with developing explicit process‐based and outcome‐based measures for adults with cirrhosis.

Financial Compensation For Hepatologists in Different Practice Settings

Mitchell L. Shiffman, Norman L. Sussman, Natarajan Ravendhran, Macia Ditmyer, Kris V. Kowdley, Marcelo Kugelmas – 26 December 2018 – Several governmental agencies and private organizations monitor data on relative value units (RVUs) and salary earned by various medical specialists. There are currently no data that define the RVU production and salary earned by hepatologists. A web‐based survey that queried the number of patients that a hepatologist cares for, RVU production, and salary support was sent to 2,587 members of the American Association for the Study of Liver Diseases.

An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study

Xiu‐Ping Zhang, Yu‐Zhen Gao, Zhen‐Hua Chen, Min‐Shan Chen, Le‐Qun Li, Tian‐Fu Wen, Li Xu, Kang Wang, Zong‐Tao Chai, Wei‐Xing Guo, Jie Shi, Dong Xie, Meng‐Chao Wu, Wan Yee Lau, Shu‐Qun Cheng – 26 December 2018 – Portal vein tumor thrombus (PVTT) is a significant poor prognostic factor for hepatocellular carcinoma (HCC). Patients with PVTT limited to a first‐order branch of the main portal vein (MPV) or above could benefit from negative margin (R0) liver resection (LR).

Subscribe to